Neurosense Income Quality from 2010 to 2026
| NRSN Stock | USD 0.87 -0.0031 -0.36% |
Income Quality | First Reported 2010-12-31 | Previous Quarter 0.89 | Current Value 0.47 | Quarterly Volatility 0.18916313 |
Macro event markers
This statements view for Neurosense Therapeutics organizes long-term performance signals with capital structure context. Key drivers include Interest Income of 2.2 K, Depreciation And Amortization of 18.8 K or Interest Expense of 373.3 K along with ratios such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 12.14. This view complements Neurosense Therapeutics Valuation and Volatility modules.
Neurosense | Income Quality | Build AI portfolio with Neurosense Stock |
Evaluating Neurosense Therapeutics's Income Quality across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Neurosense Therapeutics's fundamental strength.
Latest Neurosense Therapeutics' Income Quality Growth Pattern
Below is the plot of the Income Quality of Neurosense Therapeutics over the last few years. It is an assessment of the sustainability of a company's earnings over time, considering factors like revenue source diversification and cost structure. Neurosense Therapeutics' Income Quality historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Neurosense Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Income Quality | 10 Years Trend |
|
Income Quality |
| Timeline |
Neurosense Income Quality Regression Statistics
| Arithmetic Mean | 0.54 | |
| Geometric Mean | 0.51 | |
| Coefficient Of Variation | 35.02 | |
| Mean Deviation | 0.14 | |
| Median | 0.48 | |
| Standard Deviation | 0.19 | |
| Sample Variance | 0.04 | |
| Range | 0.7469 | |
| R-Value | 0.49 | |
| Mean Square Error | 0.03 | |
| R-Squared | 0.24 | |
| Significance | 0.05 | |
| Slope | 0.02 | |
| Total Sum of Squares | 0.57 |
Neurosense Income Quality History
About Neurosense Therapeutics Ltd
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel. Neurosense Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 11 people. Liquidity and trading activity can influence how quickly new information is reflected in Neurosense Therapeutics's price. Lower liquidity may increase execution variability. Neurosense Therapeutics has market cap of 27.11 M, ROE of -24.78%.
Methodology
Unless otherwise specified, financial data for Neurosense Therapeutics is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Neurosense (USA Stocks:NRSN) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: The dataset for Neurosense Therapeutics incorporates public filings and market reference sources and official institutional disclosures, including U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Some inputs may not update instantaneously. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Neurosense Therapeutics may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Pair Trading with Neurosense Therapeutics
Pair trading with Neurosense Therapeutics can help investors hedge some company-specific exposure by balancing a long view with an offsetting position. The key question is whether the second leg adds real hedge value instead of just creating a more complex version of the same risk.
Moving against Neurosense Stock
Pair-trading logic also applies to tax-loss harvesting: by identifying an asset with near-identical factor exposures to Neurosense Therapeutics, investors can effectively maintain a synthetic Neurosense Therapeutics position while the wash-sale clock resets.
The correlation structure around Neurosense Therapeutics evolves as market regimes change. Assets that were once uncorrelated with Neurosense Therapeutics may become correlated during crises, so investors should monitor rolling correlations alongside static long-run averages.
Pair evaluation and Correlation analysis for Neurosense Therapeutics provide hedging context. The approach can be applied within sectors or across broader universes.More Resources for Neurosense Stock Analysis
Reviewing Neurosense Therapeutics commonly begins with financial statements and performance trends. Ratios and trend metrics help frame Neurosense Therapeutics' operating context. Outlined below are key reports that provide context for Neurosense Therapeutics Stock:Compare Neurosense Therapeutics against competitors using Neurosense Therapeutics Correlation. This adds peer-relative context. To understand the process of investing in Neurosense Stock, visit our How to Invest in Neurosense Therapeutics guide.Analysis related to Neurosense Therapeutics should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Investors evaluate Neurosense Therapeutics using market value and book value, each describing different facets of the business. Neurosense Therapeutics' market capitalization is 27.11 M. With a P/B ratio of 12.82, the market values Neurosense Therapeutics well above its book equity. Enterprise value stands at 25.62 M. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Valuation methods compare these perspectives to frame context.
Value and price for Neurosense Therapeutics are related but not identical, and they can diverge across cycles. For Neurosense Therapeutics, key inputs include a P/B ratio of 12.82, and ROE of -24.78%. Market price reflects the current exchange level formed by active bids and offers.